ZTS — Zoetis Inc.

Is ZTS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of November 17, 2026

Zoetis Inc. (ZTS) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $83.48. The rating moved from Neutral to Overbought on November 13, 2026.

See all overbought Healthcare stocks →

AI analysis

Zoetis Inc. (ZTS) combines a durable, recurring-revenue business with leading market positions in companion-animal and production-animal health. The company generates strong cash flow and maintains margin resilience versus cyclical peers, enabling shareholder returns and disciplined M&A to expand specialty and biologic offerings. Near-term catalysts include continued product rollout in parasiticides and vaccines, steady demand in companion-animal care, and defensive sector flows that can support valuation. Key constraints include pricing and generic risk, macro sensitivity in discretionary veterinary spend, and execution risks around supply and acquisitions. Overall fundamentals point to steady growth and cash generation with moderate downside risk in adverse scenarios.

Key factors

  • Market leadership in animal health with deep penetration in companion-animal and livestock segments
  • Recurring, defensive revenue stream from prescription medicines, vaccines and long-life parasiticides
  • Strong free cash flow generation supporting dividends, buybacks and selective M&A
  • Diversified geographic footprint reduces single-market exposure and provides growth in emerging markets
  • Ongoing R&D and pipeline breadth in biologics, vaccines and specialty products supports medium-term growth
  • Favorable sector flows into large-cap pharma/defensive healthcare, which can support relative valuation
  • Established distribution relationships with veterinarians, pharmacies and animal-health channels

Risks

  • Pricing pressure, generic erosion or biosimilar competition in key product franchises
  • Macro-driven weakness in discretionary vet visits or producer margins that reduces demand for products
  • Regulatory, safety or labeling issues that could lead to recalls, litigation or delayed approvals
  • M&A integration execution risk for acquisitions meant to bolster specialty or biologic exposure
  • Foreign-exchange volatility given material international sales
  • Supply-chain disruptions or manufacturing-quality problems that could impair shipments and revenue timing

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ZTS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.